The PROLONG-ATE Study: A Phase 2/3 Study to Evaluate Efficacy and Safety of BAX 855,A Longer-Acting PEGylated Full-Length Recombinant Factor VIII (PEG-rFVIII),for Prophylaxis and Treatment of Bleeding in Severe Haemophilia A
Awarded/Presented
Tags
Bleeding Disorders Conference
Clinical Research
Researchers
Benny Sorensen, Julia Singer, Sandor Fritsch, Bruce Ewenstein, Wing-Yen Wong